Attached files
file | filename |
---|---|
10-K - 10-K - JUNIPER PHARMACEUTICALS INC | jnp-10k_20161231.htm |
EX-32.2 - EX-32.2 - JUNIPER PHARMACEUTICALS INC | jnp-ex322_6.htm |
EX-32.1 - EX-32.1 - JUNIPER PHARMACEUTICALS INC | jnp-ex321_7.htm |
EX-31.(I)2 - EX-31.(I)2 - JUNIPER PHARMACEUTICALS INC | jnp-ex31i2_8.htm |
EX-31.(I)1 - EX-31.(I)1 - JUNIPER PHARMACEUTICALS INC | jnp-ex31i1_9.htm |
EX-23..2 - EX-23..2 - JUNIPER PHARMACEUTICALS INC | jnp-ex232_542.htm |
EX-21 - EX-21 - JUNIPER PHARMACEUTICALS INC | jnp-ex21_11.htm |
EX-10.32 - EX-10.32 - JUNIPER PHARMACEUTICALS INC | jnp-ex1032_761.htm |
EX-10.31 - EX-10.31 - JUNIPER PHARMACEUTICALS INC | jnp-ex1031_763.htm |
EX-10.19 - EX-10.19 - JUNIPER PHARMACEUTICALS INC | jnp-ex1019_760.htm |
EX-2.2 - EX-2.2 - JUNIPER PHARMACEUTICALS INC | jnp-ex22_762.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-206928, 333-169599, 333-155530, 333-38230, 333-75275, 333-125671,333-132803, 333-140107, and 333-37976) and Form S-8 (Nos. 333-63470, 333-34079, 333-116072, 333-152008, 333-188647, 333-205723, and 333-213433,) of Juniper Pharmaceuticals, Inc. of our report dated March 7, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 7, 2017